Seres Therapeutics Inc (MCRB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Seres Therapeutics Inc (MCRB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH503774D
  • |
  • Pages: 53
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Seres Therapeutics Inc (Seres), is a microbiome therapeutics platform company that develops a novel class of biological drugs. The company creates a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. The company's lead development candidate, SER-109 is an oral microbiome therapeutic and bacterial spore ecology that is being developed for the prevention of recurrent clostridium difficile infection in adults. Seres' SER-287 is an oral therapy for the treatment of ulcerative colitis, an inflammatory bowel disease. The company utilizes its microbiome therapeutics platform to identify key alterations in the microbiome that are associated with or lead to specific diseases. Seres is headquartered in Cambridge, Massachusetts, the US.

Seres Therapeutics Inc (MCRB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Seres Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Seres Health Raises USD48 Million in Series C Venture Financing 12

Seres Health Raises USD10 Million in Series B Financing 13

Seres Health Raises USD 10.5 Million In Series A Financing Round 15

Partnerships 16

Seres Therapeutics to Enter into Partnership Agreement with MD Anderson and Parker Institute 16

Seres Therapeutics Enters into Agreement with Emulate 17

Seres Therapeutics Enters into Agreement with Massachusetts General Hospital 18

Seres Therapeutics Enters into Research Agreement with Mayo Clinic 19

Seres Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 20

Seres Therapeutics Enters into Agreement with University of Pennsylvania 21

Seres Therapeutics Forms Partnership with Research Institute of St. Joseph's Hamilton 22

Seres Therapeutics Forms Partnership with Medical University of Graz 23

Seres Health Enters into Research Agreement with Mayo Clinic 24

Licensing Agreements 25

Nestle Health Science Enters into Licensing Agreement with Seres Therapeutics 25

Seres Therapeutics Enters into Licensing Agreement with Mayo Foundation for Medical Education and Research 27

Equity Offering 28

Seres Therapeutics Raises USD153.8 Million in IPO 28

Seres Health Raises USD65 Million in Financing 30

Seres Therapeutics Inc-Key Competitors 31

Seres Therapeutics Inc-Key Employees 32

Seres Therapeutics Inc-Locations And Subsidiaries 33

Head Office 33

Other Locations & Subsidiaries 33

Recent Developments 34

Financial Announcements 34

Aug 02, 2018: Seres Therapeutics reports second quarter financial results and provides operational updates 34

May 09, 2018: Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Updates 36

Mar 08, 2018: Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates 38

Nov 08, 2017: Seres Therapeutics Reports Third Quarter 2017 Financial Results 41

Aug 03, 2017: Seres Therapeutics Reports Second Quarter 2017 Financial Results and Provides Update on Operational Progress 43

May 04, 2017: Seres Therapeutics Reports First Quarter 2017 Financial Results and Provides Update on Operational Progress 45

Mar 16, 2017: Seres Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Operational Progress Update 46

Corporate Communications 48

Sep 04, 2018: Seres Therapeutics appoints Meryl Zausner as Board Director 48

Jan 31, 2018: Seres Therapeutics Names Eric D. Shaff to Additional Role of Chief Operating Officer 49

Jul 10, 2017: Seres Therapeutics Strengthens Board of Directors with Appointment of Willard Dere, M.D., Former Amgen Chief Medical Officer 50

Clinical Trials 51

Apr 17, 2018: Seres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at the 2018 American Association for Cancer Research Annual Meeting 51

Nov 07, 2017: Seres Therapeutics Awarded Grant from CARB-X to Support Development of Microbiome Therapeutic Candidate 52

Appendix 53

Methodology 53

About GlobalData 53

Contact Us 53

Disclaimer 53

List of Figures

Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Seres Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Seres Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Seres Health Raises USD48 Million in Series C Venture Financing 12

Seres Health Raises USD10 Million in Series B Financing 13

Seres Health Raises USD 10.5 Million In Series A Financing Round 15

Seres Therapeutics to Enter into Partnership Agreement with MD Anderson and Parker Institute 16

Seres Therapeutics Enters into Agreement with Emulate 17

Seres Therapeutics Enters into Agreement with Massachusetts General Hospital 18

Seres Therapeutics Enters into Research Agreement with Mayo Clinic 19

Seres Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 20

Seres Therapeutics Enters into Agreement with University of Pennsylvania 21

Seres Therapeutics Forms Partnership with Research Institute of St. Joseph's Hamilton 22

Seres Therapeutics Forms Partnership with Medical University of Graz 23

Seres Health Enters into Research Agreement with Mayo Clinic 24

Nestle Health Science Enters into Licensing Agreement with Seres Therapeutics 25

Seres Therapeutics Enters into Licensing Agreement with Mayo Foundation for Medical Education and Research 27

Seres Therapeutics Raises USD153.8 Million in IPO 28

Seres Health Raises USD65 Million in Financing 30

Seres Therapeutics Inc, Key Competitors 31

Seres Therapeutics Inc, Key Employees 32

Seres Therapeutics Inc, Subsidiaries 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Seres Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17743
Site License
USD 500 INR 35485
Corporate User License
USD 750 INR 53228

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com